次新股異動 | 雲頂新耀-B漲超6%,上市累漲40%
uSMART友信智投10月12日消息,上市第二個交易日,次新股雲頂新耀-B延續強勁走勢,截至13:35分,漲6.25%,報77.3港元,若打新持有至今,不計手續費,賬面一手最高賺11250港元。
雲頂新耀-B於10月9日掛牌上市,首日收漲32.27%。
雲頂新耀-B的公開申購人數近31萬,其中乙組有將近1.3萬。頂頭槌申購144張,保本漲幅約40%。一手中籤率2%,是年內非常低的水平。公開認購約654.41倍,國際發售認購約27倍。星光熠熠的基石團隊包括高瓴、清池資本、奧博資本、貝萊德等16名,比嘉和生物更勝一籌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.